Complement C3

Complement C3

Complement C3 詳細

Molecule Name
Complement C3
分子の別称
Complement C3,CPAMD1
Drug Development Progress
治験薬の数13
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
Complement C3,Complement Component C3a,Epididymis Secretory Sperm Binding Protein Li 62p,C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1,C3bc,C3adesArg,C3,Complement Component C3b,Complement Component 3,C3a Anaphylatoxin,Prepro-C3,CPAMD1,Acylation-Stimulating Protein Cleavage Product,HEL-S-62p,AHUS5,ARMD9,ASP,C3a,C3b
バックグランド
C3 is the major complement component serum. It is mainly synthesized by macrophages and liver. C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. It is cleaved into two fragments, C3a and C3b. C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.

Complement C3 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Efdamrofusp alfaIBI-302Phase 3 ClinicalAP Biosciences Inc
Diabetic macular oedema; Macular Degeneration; Plaque psoriasis; Wet Macular Degeneration
詳細
NGM-621NGM-621Phase 2 ClinicalNGM Biopharmaceuticals Inc
Coronavirus Disease 2019 (COVID-19); Geographic Atrophy
詳細
RG-002-C-0106RG-002-C-0106; RG002C0106Phase 2 ClinicalBeijing Xuanjingrui Pharmaceutical Technology Co Ltd, Suzhou Xuanjing Biotechnology Co Ltd
Complement-Mediated Diseases; Glomerulonephritis, IGA; Hemolysis; Nephrotic Syndrome
詳細
APL-3007APL-3007Phase 2 ClinicalApellis Pharmaceuticals Inc
Geographic Atrophy
詳細
SGB-9768SGB-9768Phase 2 ClinicalSuzhou Sanegene Bio Inc
C3 glomerulopathy; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Kidney Diseases
詳細
KRIYA-825KRIYA-825; VV-14295Phase 2 ClinicalKriya Therapeutics Inc
Geographic Atrophy
詳細
ALXN-2030ALXN-2030Phase 2 ClinicalAlexion Pharmaceuticals Inc
Rejection of renal transplantation; Rejection of organ transplantation
詳細
LP-005LP-005; RX-001Phase 2 ClinicalLongbio Pharma (Suzhou) Co Ltd
Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies
詳細
ARO-C3ARO-C3; ARO-C-3Phase 2 ClinicalArrowhead Pharmaceuticals Inc
C3 glomerulopathy; Glomerulonephritis, IGA
詳細
CG-001CG-001Phase 1 ClinicalChengdu Konjin Co Ltd
Autoimmune Diseases; Hemoglobinuria, Paroxysmal; Myasthenia Gravis
詳細
BI-CPhase 1 ClinicalBoehringer Ingelheim International Gmbh
Geographic Atrophy; Retinal Diseases
詳細
Ebribafusp alfaADX-097Phase 1 ClinicalQ32 Bio Inc
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Nephrosis, Lipoid
詳細
NM3086NM3086; NM-3086Phase 1 ClinicalNovelMed Therapeutics Inc
Hemoglobinuria, Paroxysmal
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
PegcetacoplanAPL-2ApprovedApellis Pharmaceuticals IncAspaveli, Empaveli, SyfovreUnited StatesHemoglobinuria, ParoxysmalApellis Pharmaceuticals Inc2021-05-14
Amyotrophic Lateral Sclerosis; Anemia, Hemolytic, Autoimmune; C3 glomerulopathy; Delayed Graft Function; Geographic Atrophy; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Hemoglobinuria, Paroxysmal; Kidney Failure, Chronic; Lupus Nephritis; Macular Degeneration; Motor Neuron Disease; Rejection of renal transplantation
詳細